Last reviewed · How we verify

Standard pain management regimen

Cedars-Sinai Medical Center · Phase 3 active Small molecule

This drug works by targeting the opioid receptors in the brain to reduce pain perception.

This drug works by targeting the opioid receptors in the brain to reduce pain perception. Used for Management of moderate to severe pain.

At a glance

Generic nameStandard pain management regimen
Also known asPharmacological pain relief
SponsorCedars-Sinai Medical Center
Drug classopioid
Targetopioid receptors
ModalitySmall molecule
Therapeutic areaPain management
PhasePhase 3

Mechanism of action

The exact mechanism of action is not fully understood, but it is believed to involve the activation of opioid receptors, leading to a decrease in the transmission of pain signals to the brain. This results in a reduction in the perception of pain, providing relief to patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: